Search for dissertations about: "post kidney transplant patients"
Showing result 1 - 5 of 12 swedish dissertations containing the words post kidney transplant patients.
-
1. The balance between under- and over-immunosuppression after heart transplantation with emphasis on acute cellular rejection and chronic kidney disease. Experiences from Skåne University Hospital in Lund 1988-2010
Abstract : Background and aims:Heart transplantation (HT) constitutes the ultimate treatment choice for end-stage heart failure. Following HT, patients require life-long immunosuppressive treatment to prevent allograft rejection. READ MORE
-
2. Renal and extrarenal signs of autosomal dominant polycystic kidney disease
Abstract : The aim of the study was to evaluate the clinical impact of renal and extrarenal manifestations of ADPKD (Autosomal Dominant Polycystic Kidney Disease). For this purpose, prospective and retrospective analyses of patients with ADPKD in different populations were performed. READ MORE
-
3. Mechanisms and treatment options of chronic graft dysfunction : Experimental and clinical studies
Abstract : Chronic graft dysfunction (CGD) is an important post-transplant complication. CGD can be considered as an impaired repair process, which ultimately leads to the loss of graft function.To study non-immunological factors contributing to the development of CGD in kidney grafts we used in vitro and in vivo models, and clinical studies. READ MORE
-
4. The clinical importance of non-HLA specific antibodies in kidney transplantation
Abstract : The clinical significance of human leukocyte antigen (HLA) antibodies (Abs) for hyperacute, acute and chronic antibody-mediated rejection (AMR) of kidney allografts has been clearly demonstrated. AMR occurs in the absence of donor-reactive HLA Abs. READ MORE
-
5. Clinical consequences after heart transplantation with reference to osteoporosis, renal function, and immunosuppression. Experiences from Skåne University Hospital in Lund 1988-2019
Abstract : Background. Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure. To prevent rejection of the allograft, life-long immunosuppressive therapy is required. READ MORE